Comparative Pharmacology
Head-to-head clinical analysis: ERYC SPRINKLES versus ERYTHROMYCIN STEARATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERYC SPRINKLES versus ERYTHROMYCIN STEARATE.
ERYC SPRINKLES vs ERYTHROMYCIN STEARATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by blocking the translocation of peptidyl-tRNA. It may also act as a motilin receptor agonist, enhancing gastrointestinal motility.
Erythromycin is a macrolide antibiotic that binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by blocking the translocation of peptides.
250-500 mg orally every 6 hours (or 333 mg every 8 hours) for adults; maximum 4 g/day.
250-500 mg orally every 6 hours or 500-1000 mg orally every 12 hours; maximum 4 g/day.
None Documented
None Documented
1.5-2.0 hours in adults with normal renal function; prolonged in neonates (2-4 hours) and patients with hepatic impairment.
1.4-2 hours in adults with normal renal function; prolonged to 5-6 hours in anuria; unchanged in hepatic impairment.
Primarily biliary (fecal) elimination (60-80% as unchanged drug) with approximately 5-15% renal excretion of active drug.
Primarily excreted in bile as active drug; about 2-5% excreted renally as unchanged drug. Up to 15% excreted in feces.
Category C
Category A/B
Macrolide Antibiotic
Macrolide Antibiotic